John Paulson Purchases 1,029,098 Shares of Bausch Health Companies Inc. (NYSE:BHC) Stock

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) Director John Paulson purchased 1,029,098 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was bought at an average cost of $5.24 per share, for a total transaction of $5,392,473.52. Following the completion of the acquisition, the director now directly owns 28,222,267 shares of the company's stock, valued at $147,884,679.08. This represents a 3.78% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson bought 1,005,376 shares of Bausch Health Companies stock. The shares were acquired at an average price of $5.47 per share, with a total value of $5,499,406.72.
• On Tuesday, June 10th, John Paulson bought 754,134 shares of Bausch Health Companies stock. The stock was bought at an average price of $5.05 per share, with a total value of $3,808,376.70.

Bausch Health Companies Price Performance

BHC traded up $0.51 during midday trading on Friday, hitting $6.02. 11,490,808 shares of the company's stock traded hands, compared to its average volume of 2,611,854. The company has a market cap of $2.23 billion, a PE ratio of -50.12, a price-to-earnings-growth ratio of 0.37 and a beta of 0.28. The stock's fifty day simple moving average is $4.85 and its 200-day simple moving average is $6.41. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $9.85.

Hedge Funds Weigh In On Bausch Health Companies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank raised its position in Bausch Health Companies by 1.0% during the fourth quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock valued at $1,350,000 after acquiring an additional 1,712 shares in the last quarter. Wells Fargo & Company MN raised its position in Bausch Health Companies by 7.9% during the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after acquiring an additional 1,896 shares in the last quarter. American Century Companies Inc. raised its position in Bausch Health Companies by 10.6% during the fourth quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock valued at $220,000 after acquiring an additional 2,600 shares in the last quarter. Blair William & Co. IL raised its position in Bausch Health Companies by 3.2% during the fourth quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock valued at $683,000 after acquiring an additional 2,622 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its position in shares of Bausch Health Companies by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after purchasing an additional 3,001 shares during the period. Institutional investors own 78.65% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada raised their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Wall Street Zen lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company. According to MarketBeat.com, Bausch Health Companies presently has a consensus rating of "Hold" and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.